13/730 → 6/1334; -1.33 percentage points of formation share.
What is actually happening inside this batch of companies is a quiet split between two very different bets on what "genomics" means as a business. One track, represented by Kernal Biologics, Talus Bio, and WhiteLab Genomics, treats the genome as a drug discovery substrate, building mRNA-LNP delivery systems or AI platforms to design cell, RNA, and DNA therapies. The other track, seen in Mable, Genomelink, and Nest Genomics, treats genomic data as an already-collected asset to be routed, interpreted, and monetized through consumer apps or clinical workflow tools rather than new molecules. That split helps explain why this formation is cooling at 0.25x while adjacent categories like Biotech (0.46x) and Cancer Therapeutics and Therapeutics (both 0.45x) are growing nearly twice as fast: capital seems to be rewarding companies that build new therapeutic modalities over ones that repackage sequencing data that platforms like 23andMe and Ancestry already generated years ago. The founding dates cluster tightly in 2020 to early 2022, right as protein structure prediction and generative sequence models matured enough to make computational drug design plausible at startup scale, but that window has since narrowed as investors chase the therapeutics label directly rather than the genomics infrastructure underneath it. Underscoring that shift, current scrutiny in this space centers not on new data collection but on whether AI agents proposing experiments or genomic conclusions can maintain durable lineage back through code, parameters, and instruments, a provenance problem that matters most for the discovery-platform half of this group.
Agents that propose experiments or scientific conclusions need durable lineage from source evidence through code, parameters, instruments, intermediate results, and revisions.
Compare scientific-agent workflows with current ELN, data-lineage, model-tracking, and reproducibility systems to locate evidence breaks and manual handoffs.
Included in YC's Genomics membership during the measured recent window.
Included in YC's Genomics membership during the measured recent window.
Included in YC's Genomics membership during the measured recent window.
Included in YC's Genomics membership during the measured recent window.
Included in YC's Genomics membership during the measured recent window.
Included in YC's Genomics membership during the measured recent window.
A primary internal company segment within Genomics, derived deterministically from the shared yc industry “Drug Discovery and Delivery”. This is a classification of current window members, not a causal layer or a separate time trend.
A primary internal company segment within Genomics, derived deterministically from the shared yc tag “Health Tech”. This is a classification of current window members, not a causal layer or a separate time trend.
Measured-window members of Genomics that could not be assigned to a narrower shared YC tag or industry without forcing a classification.
No comparable outside activity is connected yet.
Cambrian Signal, “Genomics,” publication yc-2026-10-02-semantic-v8, snapshot October 2, 2026.
cambrian.jafar.com/formation/genomics